A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma and Other Solid Tumors

Trial Profile

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma and Other Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs CB 839 (Primary) ; Nivolumab
  • Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Calithera Biosciences
  • Most Recent Events

    • 19 Sep 2017 According to a Calithera Biosciences media release, data will be presented at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
    • 08 Aug 2017 According to a Calithera Biosciences media release, results from this trial are expected in the fourth quarter of 2017.
    • 09 May 2017 According to a Calithera Biosciences media release, the company expects results from this trial in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top